Candel Therapeutics Furnishes Investor Presentation Under Regulation FD

What Happened

• On September 9, 2026, Candel Therapeutics, Inc. (CADL) filed a Form 8-K reporting a Regulation FD disclosure. The company furnished an investor presentation as Exhibit 99.1 that it may use in presentations or discussions with investors, analysts, and other parties.
• The filing also includes the cover page interactive data file (Inline XBRL).

Key Details

• Filing date: September 9, 2026 (Form 8-K).
• Item reported: 7.01 Regulation FD Disclosure — investor presentation furnished as Exhibit 99.1.
• Ancillary exhibit: Exhibit 104 (Cover Page Interactive Data File) embedded in the filing.
• No other Items (e.g., earnings, executive changes, mergers) were reported in this 8-K.

Why It Matters

• Furnishing an investor presentation under Regulation FD gives all investors access to the same corporate presentation materials the company uses with analysts and investors. Review the attached Exhibit 99.1 to see any updates on strategy, pipeline, milestones, or other corporate information Candel chose to present.
• This 8-K itself does not announce financial results or executive changes; it simply makes the presentation material publicly available. Investors should read the exhibit for any substantive updates.